肺心病心力衰竭的临床治疗体会  

The Clinical Treatment Experience of Cardiopulmonary Disease

作　　者：邢君[1] 

机构地区：[1]黑龙江省双鸭山市宝山区人民医院,155100

出　　处：《中国卫生标准管理》2015年第3期167-168,共2页China Health Standard Management

摘　　要：目的探究肺心病心力衰竭患者的治疗方法和效果。方法选取2013年3月-2014年5月收治的76例肺心病心力衰竭患者进行治疗,随机分组,实验组39例患者采用低分子肝素和厄贝沙坦的联合治疗,对照组37例患者选择常规治疗,观察患者身体的恢复情况。结果实验组治疗总有效率为94.87%,对照组治疗总有效率为83.78%,两组患者的治疗效果差异显著,有统计学意义（P〈0.05）。结论肺心病心力衰竭患者采用低分子肝素和厄贝沙坦的联合治疗,可明显缓解患者的身体症状。Objective The treatment methods and treatment effect on patients with cardiopulmonary disease is to be analyzed. Methods Choose 76 patients with cardiopulmonary disease who are treated in hospital from March 2013 to May 2014 and separate them into study group and control group at random,39 patients in study group are given combination treatment of low molecular heparin and Irbesartan medicine treatment,while 37 patients in control group are given conventional treatment, and then observe patients’ recovery state. Results The efficiency rate in study group is up to 94.87%,and in control group it is 83.78%;there is a great differential between two groups,which has the statistic value（P〈0.05）.Conclusions Combination treatment of low molecular heparin and Irbesartan medicine treatment is effective to relieve symptoms of patients with cardiopulmonary disease greatly, which is worthy of being applied and promoted.

关 键 词：肺心病心力衰竭 低分子肝素 厄贝沙坦 

分 类 号：R331[医药卫生—人体生理学]